(MENAFN- GlobeNewsWire - Nasdaq) The nucleic acid therapeutics market is growing due to rising genetic and chronic disease prevalence, expanding genomics R&D, and increased RNA therapeutics adoption. Key opportunities include precision medicine demand, mRNA applications, advanced delivery platforms, AI integration, and regulatory support.

Dublin, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The "Nucleic Acid Therapeutics Market Report 2025" has been added to ResearchAndMarkets's offering.

The Nucleic Acid Therapeutics Global Market Report 2025 offers an essential resource for strategists, marketers, and senior management aiming to navigate the burgeoning nucleic acid therapeutics market. This report addresses the critical trends expected to influence the market over the forthcoming decade and beyond.

The global nucleic acid therapeutics market is poised for significant growth, expanding from $6.01 billion in 2024 to an impressive $12.24 billion by 2029. This robust growth forecast signifies a compound annual growth rate (CAGR) of 15.2% during the forecast period. This market surge is propelled by the increasing necessity for precision medicine, profound innovations in mRNA vaccine applications, and a burgeoning pipeline of nucleic acid-based therapies.

Driving market expansion are key trends such as the extension of mRNA applications into oncology and rare diseases. Also of note is the integration of artificial intelligence and machine learning into RNA drug discovery processes, alongside the development of advanced, targeted delivery systems. These trends promise to heighten the effectiveness of nucleic acid therapeutics, offering substantial promise for treating underlying genetic conditions.

The growing prevalence of genetic and chronic diseases significantly contributes to the market's momentum. Conditions such as cardiovascular illnesses, cancer, and autoimmune disorders continue to rise, necessitating innovative treatment solutions. Nucleic acid therapeutics steps up to deliver targeted, personalized interventions. For instance, the UK-based Cystic Fibrosis Trust reported an increase in registered cystic fibrosis patients, denoting the rising need and application of advanced gene-targeted therapies.

Key industry players are pioneering groundbreaking treatments. For instance, Ionis Pharmaceuticals Inc. secured FDA approval in December 2024 for TRYNGOLZ (olezarsen), marking a significant leap in treating familial chylomicronemia syndrome. Similarly, in June 2025, Novartis AG acquired Regulus Therapeutics Inc., a move to reinforce its RNA-targeted drug development capabilities and accelerate its offerings in rare and chronic disease treatments.

The major entities influencing this competitive market include Pfizer Inc., Sanofi S.A., Novartis AG, Moderna Inc., and BioNTech SE, among others. These organizations continuously innovate, offering antisense oligonucleotide therapies and expanding RNA platforms for maximum therapeutic efficacy.

Geographically, North America leads the market, with Asia-Pacific anticipated to be the fastest-growing region. Challenges such as global trade frictions affect the market, as pharmaceutical companies grapple with tariffs on APIs and lab equipment, leading to strategic shifts like the expansion of production capacities in India and Europe.

This industry's landscape is dynamically evolving, driven by technological innovations and strategic partnerships. The nucleic acid therapeutics market is not only expanding in size but also in its capacity to offer groundbreaking, life-changing therapies.

Reasons to Purchase:

• Access a holistic view encompassing 15 global geographies, supported by the most extensive available data.
• Evaluate the effects of macro factors including geopolitical upheavals, trade policies, post-pandemic supply chain changes, inflation, interest rate shifts, and regulatory transformations.
• Develop targeted regional and national strategies using localized data insights.
• Pinpoint lucrative growth segments for strategic investments.
• Leverage forecasting data to outperform competitors by identifying key market drivers and trends.
• Stay informed on consumer behavior through the latest market share analysis.
• Gauge performance against primary competitors with reliable benchmarking.
• Utilize the report for comprehensive internal and external presentations, featuring high-quality data and analysis.
• Receive the most current data updates, provided in convenient formats for data analysis, including Excel dashboards.

Key Attributes:

Report Attribute	Details
No. of Pages	250
Forecast Period	2025 - 2029
Estimated Market Value (USD) in 2025	$6.94 Billion
Forecasted Market Value (USD) by 2029	$12.24 Billion
Compound Annual Growth Rate	15.2%
Regions Covered	Global

Companies Featured

• Pfizer Inc.
• Merck & Co. Inc.
• Sanofi S.A.
• Novartis AG
• Moderna Inc.
• BioNTech SE
• Astellas Pharma Inc.
• Vertex Pharmaceuticals Incorporated
• Alnylam Pharmaceuticals Inc.
• Sarepta Therapeutics Inc.
• Arrowhead Pharmaceuticals Inc.
• Arcturus Therapeutics Holdings Inc.
• Imugene Limited
• CureVac SE
• Sangamo Therapeutics Inc.
• Beam Therapeutics Inc.
• Arbutus Biopharma Corporation
• Silence Therapeutics plc
• Copernicus Therapeutics Inc.
• Exothera S.A.

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

• Nucleic Acid Therapeutics Market

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN05112025004107003653ID1110298000